Caregiver measures for seizure control, efficacy, and tolerability of antiepileptic drugs for childhood epilepsy: Results of a preference survey

Epilepsy and Behavior

Volumn 22, Issue 3, 2011, Pages 542-547

  Perry, M Scott ^a   Swint, Charlotte ^b   Hawley, Jonathan ^c   Kohler, Sue ^c   Blake, Sarah ^c   Rask, Kimberly ^c   Sladky, John ^b   Krawiecki, Nicolas ^b  

^a Cook Children's Medical Center ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Antiepileptic drug; Efficacy measures; Pediatric epilepsy; Preference

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ACADEMIC ACHIEVEMENT; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGER; ANOREXIA; ANTICONVULSANT THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATONIC SEIZURE; BENIGN CHILDHOOD EPILEPSY; BLOOD CELL COUNT; BLURRED VISION; CAREGIVER; CHILD; CLONIC SEIZURE; COMPLEX PARTIAL SEIZURE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DISEASE CONTROL; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG TOLERABILITY; EXPECTATION; FALLING; FEMALE; GRAND MAL SEIZURE; HAIR LOSS; HEALTH SURVEY; HUMAN; HYPERACTIVITY; INFANT; INFANTILE SPASM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL DECISION MAKING; MENTAL CONCENTRATION; MYOCLONIC ASTATIC EPILEPSY; NAUSEA; NEWBORN; PARTIAL SECONDARILY GENERALIZED SEIZURE; PATIENT SATISFACTION; PRESCHOOL CHILD; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SLOWNESS; SOMNOLENCE; SPEECH DISORDER; TONIC CLONIC SEIZURE; TONIC SEIZURE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ANTICONVULSANTS; CAREGIVERS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; EPILEPSY; FEMALE; HEALTH SURVEYS; HUMANS; INFANT; MALE; TREATMENT OUTCOME;

EID: 80054995624     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.08.024     Document Type: Article

References (14)

1. Gilliam F., Kuzniecky R., Faught E., Black L., Carpenter G., Schrodt R. Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia 1997, 38:233-236.
2. Gilliam F. What we don't learn from clinical trials in epilepsy. Epilepsia 2003, 44(Suppl. 7):51-54.
3. Ben-Menachem E., Sander J.W., Privitera M., Gilliam F. Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy Behav 2010, 18:24-30.
4. Sander J.W. New antiepileptic drugs in practice: how do they perform in the real world?. Acta Neurol Scand Suppl 2005, 181:26-29.
5. Walker M.C., Sander J.W. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 1996, 46:912-914.
6. Ratcliffe J., Buxton M., McGarry T., Sheldon R., Chancellor J. Patients' preferences for characteristics associated with treatments for osteoarthritis. Rheumatology 2004, 43:337-345.
7. Begley C.E., Beghi E., Beran R.G., et al. ILAE Commission on the Burden of Epilepsy, Subcommission on the Economic Burden of Epilepsy: final report 1998-2001. Epilepsia 2002, 43:668-673.
8. Ronen G.M., Rosenbaum P., Streiner D.L. Topical review-Outcome measures in pediatric neurology: why do we need them?. J Child Neurol 2000, 15:775-780.
9. Groves R.M., Flower F.J., Coupler M.P., Lepkowski J.M., Singer E., Tourangeau R. Survey methodology 2004, Wiley, Hoboken, NJ.
10. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs: II. treatment of refractory epilepsy-report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004, 45:401-409.
11. Abou-Khalil B., Hemdal P., Privitera M.D. An open-label study of levetiracetam at individualized doses between 1000 and 3000 mg daily in patients with refractory epilepsy. Seizure 2003, 12:141-149.
12. Pinto A., Sander J.W. Levetiracetam: a new therapeutic option for refractory epilepsy. Int J Clin Pract 2003, 57:616-621.
13. Sachdeo R.C., Gates J.R., Bazil C.W., et al. Improved quality of life in patients with partial seizures after conversion to oxcarbazepine monotherapy. Epilepsy Behav 2006, 9:457-463.
14. Saetre R.C., Perucca E., Isojarvi J., et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007, 48:1292-1302.